ISSWSH in collaboration with the North American Menopause Society (NAMS) is publishing consensus recommendations for the management of genitourinary syndrome of menopause in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies.
Read the Full Article
ISSWSH is pleased to announce and recognize the Centers for Medicare and Medicaid Services (CMS) clarification of the statutory intent of “Prescription Drug Benefits” section 1860D-2(e)(2)(A) of the Social Security Act, stating that drugs for the treatment of moderate to severe dyspareunia (pain during sexual intercourse) due to menopause, are not excluded from Medicare Part D coverage when used consistent with this labeling.
ISSWSH, alongside the North American Menopause Society (NAMS), the American College of Obstetricians and Gynecologists (ACOG), and many other interested parties are committed to women’s health and particularly sexual health. James A. Simon, MD, President of ISSWSH, thanks these partners and commends CMS for this clarification that now allows women suffering from dyspareunia, to access expanded treatment options and get coverage under Medicare Part D.
View Press Release
The International Society for the Study of Women’s Sexual Health (ISSWSH) is pleased to announce the publication of its Process of Care for Management of Hypoactive Sexual Desire Disorder (HSDD) in Women in Mayo Clinic Proceedings. This milestone publication is the first to provide a consensus clinical management algorithm for the diagnosis and treatment of HSDD.
HSDD is a medical condition characterized by decreased or absent spontaneous or responsive sexual desire (i.e., sexual thoughts or fantasies) associated with negative emotional states and personal distress. Women with HSDD experience increased healthcare costs, health burden, and decreased quality of life. HSDD is the most common sexual dysfunction in women and studies in the US and Europe estimate its prevalence to be 6 – 19%. Recent research and increasing public awareness of HSDD will increase the number of women seeking treatment from healthcare professionals. The Process of Care for HSDD was developed to meet this unmet need.
Developed by 17 international expert panelists representing multiple healthcare disciplines and clinical specialties, the ISSWSH Process of Care for HSDD in Women provides evidence-based guidelines for the identification, diagnosis and treatment of this disorder in women that can be followed by non-expert primary care professionals and sexual medicine experts alike. The Process of Care algorithm emphasizes biopsychosocial assessment and education, highlights opportunities to address modifiable factors, includes patient needs and preferences in the decision-making process, delineates evidence-based treatment options informed by reproductive status, and defines situations for specialized referral. A separate ISSWSH panel of experts previously published a consensus white paper review on the epidemiology, nomenclature, pathophysiology and treatment strategies for HSDD for non-sexual medicine experts in Mayo Clinic Proceedings.
ISSWSH is a not-for-profit multidisciplinary, academic and scientific organization dedicated to supporting the highest standards of ethics and professionalism in research, education, and clinical practice of women's sexual health. More information about the society and its activities can be obtained at: http://www.isswsh.org.
Funding for the development of this Process of Care was provided by ISSWSH through unrestricted educational grants from Valeant Pharmaceuticals International, Inc, AMAG Pharmaceuticals, Emotional Brain BV, and Palatin Technologies, Inc. The process of care algorithm was wholly developed under the auspices of ISSWSH with no participation or influence from industry.